KYAN's mission is to

BRIDGE THE ​CANCER CARE GAP

by advancing revolutionary technologies

ADDRESSING THE CORE ​CHALLENGE OF ​CANCER TREATMENT

There is no silver bullet to treat cancer patients.

Cancer is not a single disease, but rather a group of diseases.

In total there are more than 100 different types of cancers that are ​dynamically expressed in each patient.

Identifying combinations therapies at different dosages is necessary when searching for the best cancer treatment. However, neither humans nor Big Data AI/ML can efficiently solve for large and complex set of predictions.

Our Technology

Our revolutionary phenotypic response technology is highly efficient in identifying safe and effective ​drug-dose combinations based on small inputs of data


EXPERIMENTAL BIOLOGY

Prospective experiments that identify the optimal phenotypic response surface across different biological models

SMALL DATA AI

SMALL DATA AI

Efficiently solve large and dynamic complex systems through a minimum number of tests

Efficiently solve large and dynamic complex systems through a minimum number of tests

Addition Symbol

Clinical Decision Support

People team puzzle teamwork concept

We are building a Truly Personalized Medicine Solution that will help ​oncologists give cancer patients the tailored treatments they need


How it works

Tumor with Target
Blood Sample Icon Design

Liquid/Solid Biopsy


We separate the tumor ​cells while still fresh so that ​the cancer can be tested in ​its current state

Cubic Matrix Geometric Icon
Matrix in modern style. Web banner template.
Semi-Detailed 24 Well Plate

Proprietary Drug Screening


Since any patient sample is ​limited in cells, we maximize the ​use with a proprietary design of ​experiments which gives us the ​right data to analyze



Computer
Wireframe Polygonal Globe Outline

Computational Analysis


Our computational method ​maps each patient’s individual ​results for highly accurate ​drug response predictions


health report
Doctor

Report and Insights


Clinicians receive a clear and ​comprehensive report to ​better guide treatment for ​patients

Benefits of our approach

UNIQUE data and treatments for each patient's as their ​own cancer cells are used for drug response analysis


VAST number of regimens are evaluated tomaximize ​finding effective treatment


ALL actionable treatments within a drug set can be ​ranked and compared, including against standard care

How we are different from standard care and other options

Crowd of Pictogram People
Hospital Prescription Icon

STANDARD THERAPY

SAME treatment for all patients ​and most will fail, requiring ​multiple lines of treatment

Pictogram Men Standing
Task List

PRECISION MEDICINE

SMALL chance that patients have ​identifiable biomarkers matched ​with therapy (est. < 10%)

Person icon
Numbered List

DRUG SENSITIVITY

LIMITED results when ​screening single drugs and ​preselected combinations

Biopharma Services

Target Icon

New target prioritization

Large search discovery for new targets + combinations

Unlock Private

combination discovery

Explore combination discovery for lead targets

Sine

DOSE

OPTIMIZATION

Retrospective or prospective studies to support dose optimization within trials


Identification Icon

Biomarker Identification

Find biomarker signatures based on phenotypic response curves


Arrow Forming Circle

Revive

Failed Assets

Find new combination partners or companion Dxfor assets that failed trials


Our Team

Hugo Saavedra

CEO

Lisa Chow

COO

Masturah Rashid

Head, R&D

Chih-Ming Ho

Scientific Co-founder

Edward Chow

Scientific Co-founder

Dean Ho

Scientific Co-founder

Advisors

Andreas Voss

Chief Medical ​Advisor

Phal Singh

Chief Financial ​Advisor

Rasha Kandil

Chief Regulatory ​Advisor

Wee Joo Chng

Director,National ​University Cancer ​Institute, Singapore


Carl Firth

Founder and CEO

ASLAN ​Pharmaceuticals


Katherine Wang

Project Director, ​Oncology Ascendis ​Pharma A/S


Aleidy Silva

Lead Field ​Applications Scientist ​Berkeley Lights


NEWS

September 2022

August 2022

June 2022


KYAN Therapeutics and Curie ​Oncology Announce ​Collaboration to Provide ​Personalized Cancer Test

May 2022

April 2022

Clinical Data on KYAN's ​personalized oncology ​platform presented at the

2021 ASH

Annual Meeting

November 2021

Data on Novel HDACi ​Targeting KRAS-mutated ​Cancers presented at the

AACR-KCA

Joint Conference on Precision ​Medicine in Solid Tumors


No​vember 2021

November 2021

August 2021​

Publications